Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

 Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

Shots:

  • The approval is based on multiple trial study assessing Nuzyra and resulted in safe, efficacious and well tolerated results
  • Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and  ABSSSI
  • Post marketing approval, Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics, with its expected marketing in Q1’19

Click here to read full press release/ article | Ref: Paratek Pharmaceuticals | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post